Advertisement

Reactions Weekly

, Volume 1736, Issue 1, pp 157–157 | Cite as

Pembrolizumab

Haemophagocytic lymphohistiocytosis, hypophysitis and pituitary insufficiency: case report
Case report
  • 35 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

A 58-year-old woman developed haemophagocytic lymphohistiocytosis and pituitary insufficiency secondary to hypophysitis during treatment with pembrolizumab for metastatic breast cancer.

The woman was diagnosed with stage IIB oestrogen receptor positive, progesterone receptor positive and HER2 negative breast cancer 16 years prior. She underwent partial mastectomy and received adjuvant chemotherapy with cyclophosphamide and doxorubicin. She also underwent bilateral salpingo-oophorectomy and received anastrozole for 10 years. However, the disease metastasisd to ureter, and she was diagnosed with oestrogen receptor positive, progesterone receptor negative and HER-2 negative invasive ductal carcinoma. She was treated with palbociclib plus letrozole, followed by single-agent...

Reference

  1. Al-Samkari H, et al. Haemophagocytic lymphohistiocytosis complicating pembrolizumab treatment for metastatic breast cancer in a patient with the PRF1A91V gene polymorphism. Journal of Medical Genetics 56: 39-42, No. 1, Jan 2019. Available from: URL: http://doi.org/10.1136/jmedgenet-2018-105485 - USA

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations